Cancer-causing protein may heal damaged spinal cord and brain cells

June 28, 2006

NEW YORK, NY- Cancer researchers at Columbia University Medical Center have found that a protein known for driving the growth of cancer also plays a surprising role in restoring the ability of neurons to regenerate, making it an important target for addressing spinal cord damage or neurological diseases like Alzheimer's. The research will be published in the journal Nature and will be available Wednesday, June 28 on the journal's web site.

"Our finding suggests that the same process this protein uses for proliferating cancer could also potentially be used to regrow axons that are damaged in spinal cord injuries or neurological diseases," said Antonio Iavarone, M.D., associate professor of neurology and pathology at Columbia University Medical Center's Institute for Cancer Genetics, and the study's lead author.

The proteins - known as Id proteins - are abundant in the cells of many different types of cancer, including brain, breast cancer and pediatric tumors, and were known to promote tumor growth and aid in the spread of cancer.

While searching for ways to attack Id's cancer-causing properties, Dr. Iavarone and Anna Lasorella, M.D. assistant professor of pediatrics and pathology at the Institute for Cancer Genetics, discovered the surprising neuron-healing properties of Id proteins.

Their initial findings, also published in the Nature paper, are significant for potential cancer therapies. The researchers found that an enzyme inside normal cells - called APC - usually degrades Id proteins soon after they're produced, but cancerous cells show a very high level of Id proteins. This suggests that re-introducing the APC enzyme into cancer cells could eliminate the proteins and arrest the growth of tumor cells - something that researchers will now investigate.

Spurring Neuronal Regrowth

Among neurons, however, Dr. Iavarone and Dr. Lasorella examined the Id protein potential for promoting growth, rather than arresting it. The researchers wanted to use the power of Id proteins to stimulate growth of axons - the structures on neurons responsible for transmitting electrical signals in the brain and spinal cord. But to do that they needed to overcome the problem of the APC enzyme, which degrades the protein in normal cells. So they constructed a "super" Id protein that would resist degradation from the APC enzyme, allowing it to promote axonal growth.

Normally neurons cannot regenerate damaged axons because of the presence of myelin, a substance that surrounds the axons, but the degradation-resistant "super" Id protein was able to promote axon growth even in the presence of myelin.

Dr. Iavarone added that there is no chance that such a therapy would cause cancer in the brain or spinal cord. "Neurons have completely lost the ability to create new cells so there's no danger of creating a tumor. The only growth they're capable of is regeneration of their axons," he said.
-end-
Columbia University Medical Center provides international leadership in pre-clinical and clinical research, in medical and health sciences education, and in patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, nurses, dentists, and public health professionals at the College of Physicians & Surgeons, the College of Dental Medicine, the School of Nursing, the Mailman School of Public Health, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. www.cumc.columbia.edu

Columbia University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.